from Cancer Connect
The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non small cell lung cancer due to the advancement of precision cancer medicines and immunotherapy.
Lung cancer remains the second most common cancer in women (behind breast cancer) and also the second most common in men (behind prostate cancer). In 2018, there will be approximately 225,000 individuals diagnosed with lung cancer in the United States.
Staying informed with the latest news on the prevention, screening of high risk individuals, and treatment advances are all important in order to reducing the risk of developing lung cancer and ensure optimal care and achieve the best possible outcomes.
Featured This Month on Cancer Connect
Our Favorite Advocacy Organizations & Cancer Resources
The Bonnie J. Addario Lung Cancer Foundation (ALCF) one of the largest philanthropies (patient-founded, patient-focused, and patient driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment.
The Lung Cancer Alliance is the only national non-profit organization dedicated to providing information, support and advocacy for people living with lung cancer and those at risk for the disease. Services include live referral, information and support, national awareness campaigns and advocating for multiple millions in public health dollars for lung cancer research.
CancerConnect partnered with Dana-Farber Cancer Institute to provide you with the opportunity to engage with a lung cancer expert, David M. Jackman, MD, who answered questions and relayed important information about lung cancer. Dr. Jackman is a thoracic oncologist in the Lowe Center for Thoracic Oncology at Dana-Farber. Dr. Jackman focuses on lung cancer and mesothelioma. His clinical research interests include evaluating how to predict responses to targeted therapy in non-small cell lung cancer (NSCLC).